Ozempic Reviews: What Real Users Say About the Lawsuits, Side Effects, and Results

What do real Ozempic reviews actually say?

Unlike Reddit, which mixes brand-name, compounded, and off-label chatter into one running conversation, Drugs.com sorts its reviews by the specific product someone actually filled — so the Ozempic numbers there are genuinely about Ozempic, not a semaglutide blend. As of this month, Ozempic sits at 6.7 out of 10 across roughly 1,700 reviews, with about 52% of reviewers reporting a positive experience and 22% reporting a negative one. Narrowed to the reviews specifically filed under its FDA-approved use, type 2 diabetes, the number holds almost exactly steady: 6.7 out of 10 across 1,224 reviews, 51% positive and 22% negative.

The more interesting data point is smaller and newer. A 2026 study in the Journal of Medical Internet Research ran a thematic analysis on 60 self-selected Ozempic reviews from Drugs.com, coding them for weight and appetite change, non-weight side effects, and stated plans to continue or quit. About two-thirds of reviewers described reduced appetite, fewer cravings, or actual weight loss. Gastrointestinal complaints showed up in 62% of the reviews — but here's the part worth sitting with: GI symptoms didn't meaningfully predict whether someone rated the drug highly or planned to keep taking it. What did predict low satisfaction and quitting was minimal weight loss paired with a non-GI side effect, like fatigue or headache. In plain terms, reviewers tolerated a rough stomach far more readily than they tolerated not seeing results.

Reddit's r/Ozempic runs somewhere around 147,000 members by third-party subreddit-analytics estimates, and the recurring threads there track a fairly stable set of subjects: the rough first few weeks on a starting dose, blood-sugar logs alongside weight updates (since a meaningful share of posters are actually managing diabetes, not just chasing a number on the scale), insurance and prior-authorization frustration that gets sharper when the reason for the prescription is weight loss rather than diabetes, and "food noise" quieting down as a genuinely surprising early effect people didn't expect from a diabetes drug.

If it's specifically the FDA-approved weight-loss pen you're actually trying to weigh, that's a different review pool with its own dosing ladder and its own lawsuit numbers — see Wegovy reviews. And if the compounded or sublingual-drops side of this market is what you're really sorting through, semaglutide reviews covers that angle in full.

Is there a real Ozempic lawsuit — and what's it actually about?

Yes, and there are two of them, which is a source of a lot of the confusion in search results. The larger one, MDL 3094 in the Eastern District of Pennsylvania, consolidates federal claims alleging gastroparesis, intestinal obstruction, and related severe GI injury from GLP-1 drugs including Ozempic. Case counts reported across legal-tracking sites this month range from about 3,850 to just over 4,000, depending on exactly when the count was pulled — it's a fast-growing docket, not a fixed number. Judge Karen S. Marston has reserved September 10 through 18, 2026 for Rule 702 expert hearings covering causation, warnings, and preemption; no bellwether trial date has been set, and no verdict or settlement has occurred.

The second, newer case is MDL 3163, created December 15, 2025, specifically for claims that GLP-1 drugs caused NAION, a rare form of sudden vision loss. The panel that created it explicitly declined to fold these claims into MDL 3094, deciding NAION was a distinct-enough injury to warrant its own docket. Reported counts on this docket move fast and vary by tracker; alongside it sits a parallel set of consolidated state-court claims in New Jersey. Pretrial fact discovery has a deadline in October 2026; again, no trial, verdict, or settlement has happened.

Both cases are legal arguments about whether Novo Nordisk's warning labels were adequate, not rulings that Ozempic caused anyone's specific injury — that distinction matters more than the case-count headline. One regulatory fact worth knowing alongside the litigation: in January 2025, Ozempic's own label was updated to state it's "not recommended in patients with severe gastroparesis," a caution about who shouldn't start the drug, not an admission that it causes the condition.

What do Ozempic users say about side effects on Reddit?

The complaint list is consistent across every source checked, and it maps closely to the drug's own mechanism: semaglutide slows stomach emptying and turns down appetite signals, and most of what people describe in the first weeks traces back to that single change.

• Nausea — the most frequently mentioned complaint, usually strongest in the days right after a dose increase
• Vomiting — less common than nausea, and more likely early in treatment
• Diarrhea and constipation — sometimes both, at different points in the same person's experience
• Fatigue — often tied by reviewers to eating meaningfully less, rather than described as a standalone symptom
• Injection-site irritation — mentioned far less often than the GI complaints above

The nuance worth repeating from the JMIR study above: GI complaints were common, showing up in well over half the reviews analyzed, but they weren't what separated a five-star review from a one-star one. Reviewers who lost meaningful weight tended to stay positive even through a rough stomach; reviewers who didn't lose much weight, or who developed a side effect outside the GI list, were the ones more likely to quit and say so in writing.

Do the vision-loss lawsuit claims mean Ozempic is dangerous?

This is worth answering carefully, because the science itself is still unsettled, not just the litigation. NAION is a rare condition to begin with — sudden, typically permanent vision loss caused by reduced blood flow to the optic nerve — and several retrospective studies published over the past two years have found an elevated relative risk among semaglutide users, with estimates ranging from roughly double to nearly four times the risk depending on the study's design and population. But the largest study to date, drawing on around 37 million adults with type 2 diabetes, found a smaller increase in NAION risk than those earlier, smaller studies suggested.

Put those two things together and the honest read is: there's a real, still-debated safety signal, not a settled finding either way, and because NAION itself is so rare to begin with, even a doubled or tripled relative risk translates to a small absolute number of people affected. Ozempic's FDA label doesn't currently carry a boxed warning for NAION, even as the litigation over whether patients were adequately warned continues to play out in court. Those are two different processes moving on two different timelines — regulatory review and civil litigation — and one hasn't caught up to (or contradicted) the other yet.

Ozempic for diabetes vs. off-label for weight loss — do reviews and dosing differ?

This is the split that most Ozempic-specific searches eventually run into, and it's worth stating plainly: Ozempic is FDA-approved only for type 2 diabetes. It has never been approved for weight loss, at any dose, for anyone. Its approved maintenance doses run 0.5mg, 1mg, and 2mg weekly, with 2mg cleared as the ceiling based on the SUSTAIN FORTE trial, which tested it head-to-head against the 1mg dose in people with diabetes — full chart in Ozempic dosage. Wegovy, by contrast, is the same molecule approved specifically for chronic weight management, dosed up through 2.4mg as its standard maintenance strength.

That's also the answer to a specific, common search: reviews describing "Ozempic 2mg for weight loss" are almost always either a diabetes patient at Ozempic's approved ceiling who's also losing weight as a secondary effect, or someone using Ozempic off-label who's capped at that same 2mg because it's the highest dose the product comes in — not a step toward Wegovy's higher ladder, which simply isn't available under the Ozempic label. In its own SUSTAIN trial program, semaglutide at diabetes doses has generally produced weight loss in the high-single-digit to low-double-digit percentage range, noticeably less than the roughly 15% or more Wegovy's own STEP trials reported in people without diabetes on the higher dose. That gap is largely about dose ceiling and trial population, not a sign the drug works differently depending on what it's called.

Insurance tends to follow the label closely here. Because Ozempic's approval is diabetes-specific, most insurers require a type 2 diabetes diagnosis, and often lab evidence to support it, before they'll cover it — weight-loss-only use is typically treated as off-label and billed as self-pay. That's where a strong review and an affordable one can pull apart; what Ozempic actually costs breaks down the real pathways, from insured copays to full retail.

What happens after stopping Ozempic — do reviewers regain weight?

This is one of the more searched, least discussed questions in these reviews, and the clearest data on it doesn't come from Ozempic's own trials — it comes from the STEP 1 extension study, which followed people who stopped semaglutide at the 2.4mg weight-management dose (Wegovy's dose, not Ozempic's 2mg ceiling, worth flagging since the two aren't identical populations). Within a year of stopping, participants regained about two-thirds of the weight they'd lost, along with a partial drift back in blood pressure and other metabolic markers. It's the closest published extension data available, and it's reasonable to expect a broadly similar pattern at Ozempic's lower dose, even without a dedicated Ozempic-specific extension trial to confirm the exact percentage.

On the specific "how to not gain weight back" question that shows up constantly in these threads: there's no supplement, hack, or habit that's been shown to fully substitute for continued treatment once it stops working on your appetite signals again. A broader review pooling multiple GLP-1 discontinuation studies did find that weight regain tended to be smaller when a dose was reduced gradually alongside continued lifestyle changes, compared with stopping abruptly — a finding worth knowing about, and worth raising with whoever manages your prescription if or when stopping is on the table, rather than something to plan around on your own.

Reading these reviews from a perimenopause angle

Fatigue, joint aches, and shifting digestion are already part of perimenopause's own vocabulary, with no drug involved at all — which makes a Reddit thread about Ozempic genuinely harder to parse at 40-plus than it would be at 25. If you're also managing type 2 diabetes, there's a third variable layered on top: blood-sugar swings themselves cause fatigue and brain fog independent of anything semaglutide is doing, which means a tired, foggy week could reasonably trace back to any one of three overlapping systems.

• Dose-linked symptoms tend to spike within a day or two of an injection or dose increase and ease over the following week or two — a perimenopausal version of the same fatigue or GI upset tends to drift on its own schedule, unconnected to your injection day
• Glucose-linked fatigue tends to track with meal timing and blood sugar readings, if you're checking them, rather than with how recently you took your shot
• Joint aches from the drug, when reported at all, tend to read as flu-like and cluster right after a dose change; perimenopausal joint stiffness tends to show up more symmetrically and settle in gradually, independent of any dosing schedule

A simple running note of symptom onset against dose-change dates, and glucose readings if that applies to you, gives a prescriber something concrete to sort through — more useful than guessing at which of three plausible causes is behind any one bad week.

So — is Ozempic worth it? Bottom line

For its actual, FDA-approved job — managing type 2 diabetes — the review record holds up reasonably well: a 6.7-out-of-10 aggregate is a respectable showing for a chronic-disease medication, and the two federal lawsuits attached to its name are unresolved fights over warning labels, not proof the drug is unsafe when used as prescribed. The honest caveat sits with off-label weight-loss use: real reviewers do lose meaningful weight on Ozempic, and the same appetite-quieting mechanism that helps with diabetes clearly does something for the scale too, but the drug wasn't dosed or approved for that job the way Wegovy was, and insurance is unlikely to help pay for it if weight loss is the only reason it's being prescribed.